The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs

By U. Wellner, Jörg Schubert, U. Burk, O. Schmalhofer, F. Zhu, Annika G. Sonntag, B. Waldvogel, C. Vannier, D. Darling, A. Hausen and 10 more. Nature Cell Biology, 2009

1,724 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/054ab184c86f070f089a1e5d2b87c6a452c11a2b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. M. Nieto
2. M. Tomic‐Canic
3. R. Huang
4. Claudia Cava
5. Yibin Kang
6. Danish H Sayed
7. J. P. Thiery
8. Isabella Castiglioni

In Molecular Biology

1. M. Nieto
2. J. P. Thiery
3. Yibin Kang
4. R. Huang
5. J. Shim
6. Bowen Du
7. Anurag Singh
8. J. Settleman

In Oncology

1. M. Nieto
2. J. P. Thiery
3. R. Weinberg
4. R. Huang
5. Yibin Kang
6. J. Shim
7. Bowen Du
8. Anurag Singh

Citations in the corpus

• Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer (2016, background): “However, ZEB1 and ZEB2 can also inhibit miR-200 family expression, thus forming a negative feedback loop [102,103].”
• Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. (2010, neutral): “Highly invasive tumors express high levels of ZEB1, which appears to be essential for the expansion of primary and metastic pancreatic and colorectal tumors (Wellner et al., 2009).”
• Epithelialization in Wound Healing: A Comprehensive Review (2014, background): “Furthermore, miR-203 can also target Bmi-1, a component of the polycomb repressor complex 1 involved in migration and invasion of cancer cell lines.(100) In addition, miR-205 overexpression, which targets lipid phosphatase SHIP2 and increases keratinocyte migration during wound healing,(101) has bee”
• The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis (2022, background): “The ubiquitin ligase Siah is a novel regulator of Zeb1 in breast cancer.”
• Epithelial-mesenchymal plasticity in cancer progression and metastasis (2019, background): “ZEB1 is also shown to confer stem cell properties in mouse and human breast, pancreatic and colorectal cancer cells by repressing stemness-inhibiting microRNAs such as miR-200s, miR-183 and miR-203, which further control the expression of other stem-cell-associated factors including BMI1, SOX2 and K”
• MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy (2011, neutral): “miR-200 loss is common in aggressive lung, prostate and pancreatic cancer”
• EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer (2010, background): “A role for Zeb1 in modulating CSC biology has now been established (Wellner et al., 2009).”
• Epithelial-mesenchymal transitions in development and disease. (2009, background): “Interestingly, Zeb1 is also able to confer stem cell-like properties, reinforcing the relationship between EMT and stemness (Wellner et al., 2009).”
• Distinct EMT programs control normal mammary stem cells and tumour-initiating cells (2015, neutral): “5d), a master regulator of TICs under a variety of settings 26-28 .”
• EMT, MET, plasticity and tumor metastasis (2020, background): “Corroborating the importance of Zeb1 in pancreatic cancer, short hairpin knockdown of ZEB1 in two human pancreatic cancer lines decreases progression in an orthotopic transplantation mouse model [28].”
• Cholangiocarcinoma 2020: the next horizon in mechanisms and management (2020, neutral): “Indeed, EMT-TFs, such as ZEB1, regulate expression of CSC markers by inhibiting miR-200 family members, well-known potent stemness repressors 190 .”